Literature DB >> 16141412

Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction.

Günter Giebing1, Markus Tölle, Jana Jürgensen, Jenny Eichhorst, Jens Furkert, Michael Beyermann, Frank Neuschäfer-Rube, Walter Rosenthal, Walter Zidek, Markus van der Giet, Alexander Oksche.   

Abstract

Urotensin II (UII), which acts on the G protein-coupled urotensin (UT) receptor, elicits long-lasting vasoconstriction. The role of UT receptor internalization and intracellular trafficking in vasoconstriction has yet not been analyzed. Therefore, UII-mediated contractile responses of aortic ring preparations in wire myography and rat UT (rUT) receptor internalization and intracellular trafficking in binding and imaging analyses were compared. UII elicited a concentration-dependent vasoconstriction of rat aorta (-log EC50, mol/L:9.0+/-0.1). A second application of UII after 30 minutes elicited a reduced contraction (36+/-4% of the initial response), but when applied after 60 minutes elicited a full contraction. In internalization experiments with radioactive labeled VII ((125)I-UII), approximately 70% of rUT receptors expressed on the cell surface of human embryonic kidney 293 cells were sequestered within 30 minutes (half life [t(h)]: 5.6+/-0.2 minutes), but recycled quantitatively within 60 minutes (t(h) 31.9+/-2.6 minutes). UII-bound rUT receptors were sorted to early and recycling endosomes, as evidenced by colocalization of rUT receptors with the early endosomal antigen and the transferrin receptor. Real-time imaging with a newly developed fluorescent UII (Cy3-UII) revealed that rUT receptors recruited arrestin3 green fluorescent protein to the plasma membrane. Arrestin3 was not required for the endocytosis of the rUT receptor, however, as internalization of Cy3-UII was not altered in mouse embryonic fibroblasts lacking endogenous arrestin2/arrestin3 expression. The data demonstrate that the rUT receptor internalizes arrestin independently and recycles quantitatively. The continuous externalization of rUT receptors provides the basis for repetitive and lasting UII-mediated vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141412     DOI: 10.1161/01.RES.0000184670.58688.9F

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

Review 2.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

Review 3.  GPCR Signaling and Trafficking: The Long and Short of It.

Authors:  Nathan J Pavlos; Peter A Friedman
Journal:  Trends Endocrinol Metab       Date:  2016-11-23       Impact factor: 12.015

Review 4.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

5.  Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

Authors:  N D Doan; T T M Nguyen; M Létourneau; K Turcotte; A Fournier; D Chatenet
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists.

Authors:  Rémi Magnan; Bernard Masri; Chantal Escrieut; Magali Foucaud; Pierre Cordelier; Daniel Fourmy
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

7.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

8.  Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.

Authors:  Ahmet Mesut Onat; Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Tuncer Demir; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Mehmet Sayarlioglu; Bunyamin Kisacik
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

9.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

Review 10.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.